Startseite Chitosan surface modified PLGA nanoparticles loaded with brigatinib for the treatment of non-small cell lung cancer
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Chitosan surface modified PLGA nanoparticles loaded with brigatinib for the treatment of non-small cell lung cancer

  • Muqtader Mohammed EMAIL logo , Mansour S. Alnafisah , Md. Khalid Anwer EMAIL logo , Farhat Fatima , Bjad K. Almutairy , Saad M. Alshahrani , Abdullah S. Alshetaili , Ahmed Alalaiwe , Mohamed H. Fayed , Ahmad Z. Alanazi , Mohammed Al Zahrani , Mohammad M. Hailat und Ramadan Al-Shdefat
Veröffentlicht/Copyright: 22. Oktober 2019
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

In the current study, surface-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) of brigatinib (BRB) were prepared by studying the variables PLGA (polymer), PVA (stabilizer) and chitosan (coater) against experimentally obtained responses. The optimized NPs (F2) were evaluated in vitro for differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), particle size, polydispersity index (PDI) and drug entrapment (EE), in vitro release, hematocompatibility and in vitro anticancer studies. The optimized NPs’ (F2) composition, PLGA (75 mg), PVA (0.55% w/v), chitosan (0.75% w/v) and 30 mg of BRB was found to be optimum with particle size (406.3 ± 5.1 nm), PDI (0.277), ζ potential (30.4 ± 3.3 mV) and %EE (82.32%). The in vitro release profile showed a sustained release pattern of the F2 nanoparticles of BRB. The 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay revealed a significant anticancer activity for F2 NPs against A549 cell lines in comparison to free BRB. The result obtained in this work indicated the immense potential of nanoparticles to effectively deliver the BRB to the cancer site for the treatment of non-small cell lung cancer.

Acknowledgements

This project was supported by the Deanship of Scientific Research at Prince Sattam Bin Abdulaziz University under the research project no. 2019/03/10912.

  1. Conflict of interest statement: The authors declare no conflict of interests associated with this study.

References

[1] Approved Drugs – Brigatinib. 2017. Retrieved from https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm. Accesssed 25 July, 2017.Suche in Google Scholar

[2] Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, Liu M, Yuan Y. Front. Oncol. 2019, 8, 557.10.3389/fonc.2018.00557Suche in Google Scholar PubMed PubMed Central

[3] Zhao P, Peng L, Wu W, Zheng Y, Jiang W, Zhang H, Tong Z, Liu L, Ma R, Wang L, Yao M, Wang K, Fang W, Wu L. Oncologist 2018, ii, 2018–2439.Suche in Google Scholar

[4] Alberg A, Nonemaker J. Semin. Respir. Crit. Care Med. 2008, 29, 223–232.10.1055/s-2008-1076742Suche in Google Scholar PubMed PubMed Central

[5] Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW, Groen HJ. Ann. Oncol. 2015, 26, 902–907.10.1093/annonc/mdv061Suche in Google Scholar PubMed

[6] Chs.gov.sa. 2018. http://www.chs.gov.sa/Ar/HealthCenters/NCC/CancerRegistry/CancerRegistryReports/2013.pdf.Suche in Google Scholar

[7] Cancer.org. Key statistics for lung cancer. 2018. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html.Suche in Google Scholar

[8] Cheikh A, Majjaoui S, Ismaili N, Cheikh Z, Bouajaj J, Nejjari C, Hassani A, Cherrah Y, Benjaafar N. Rabat. The Pan. Afr. Med. J. 2016, 23, 209.10.11604/pamj.2016.23.209.7750Suche in Google Scholar

[9] Highlights of prescribing information. ALUNBRIG® (brigatinib) tablets, for oral use initial U.S. approval: 2017. FVG. https://www.alunbrig.com/assets/pi.pdf.Suche in Google Scholar

[10] Gentile P, Chiono V, Carmagnola I, Hatton P. Int. J. Mol. Sci. 2014, 15, 3640–3659.10.3390/ijms15033640Suche in Google Scholar PubMed PubMed Central

[11] Mir M, Ahmed N, Rehman AU. Colloids Surf. B Biointerf. 2017, 159, 217–231.10.1016/j.colsurfb.2017.07.038Suche in Google Scholar PubMed

[12] Anwer MK, Mohammad M, Ezzeldin E, Fatima F, Alalaiwe A, Iqbal M. Int. J. Nanomed. 2019, 14, 1587–1595.10.2147/IJN.S195048Suche in Google Scholar PubMed PubMed Central

[13] Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. Pharmaceutics 2017, ii, E53.10.3390/pharmaceutics9040053Suche in Google Scholar PubMed PubMed Central

[14] Pandit J, Sultana Y, Aqil M. Artif. Cells Nanomed. Biotechnol. 2016, 45, 1397–1407.10.1080/21691401.2016.1243545Suche in Google Scholar PubMed

[15] Dina R and Hans-Georg S. Microb. Biotechnol. 2009, 2, 186–201.10.1111/j.1751-7915.2008.00080.xSuche in Google Scholar PubMed PubMed Central

[16] Aranaz I, Panos I, Peniche C, Heras A, Acosta N. Molecules 2017, 22, E1980.10.3390/molecules22111980Suche in Google Scholar PubMed PubMed Central

[17] Lu B, Lv X, Le Y. Polymers 2019, 11, 2–14.10.3390/polym12010002Suche in Google Scholar

[18] De Jong WH, Borm PJ. Int. J. Nanomed. 2008, 3, 133–149.10.2147/IJN.S596Suche in Google Scholar

[19] Jorquera P, Tripp R. Vaccines 2016, 4, pii. E45.10.3390/vaccines4040045Suche in Google Scholar

[20] Shen S, Wu Y, Liu Y, Wu D. Int. J. Nanomed. 2017, 12, 4085–4109.10.2147/IJN.S132780Suche in Google Scholar

[21] Singh S, Verma D, Mirza MA, Das AK, Dudeja M, Anwer MK, Sultana Y, Talegaonkar S, Iqbal Z. J. Drug Deliv. Sci. Technol. 2017, 39, 95–103.10.1016/j.jddst.2017.03.007Suche in Google Scholar

[22] Anwer MK, Al-Shdefat R, Ezzeldin E, Alshahrani SM, Alshetaili AS, Iqbal M. Front. Pharmacol. 2017, 8, 844.10.3389/fphar.2017.00844Suche in Google Scholar

[23] Anwer MK, Al-Mansoor MA, Jamil S, Al-Shdefat R, Ansari MN, Shakeel F. Int. J. Biol. Macromol. 2016, 92, 213–219.10.1016/j.ijbiomac.2016.07.002Suche in Google Scholar

[24] Alshahrani SM, Mohammad M, Anwer MK, Fatima F, Alshetaili AS, Alalaiwe A, Alsulays BB, Shakeel F. Acta Pol. Pharm. 2019, 76, 225–232.10.32383/appdr/94616Suche in Google Scholar

[25] Choi J, Reipa V, Hitchins VM, Goering PL, Malinauskas RA. Toxicol. Sci. 2011, 123, 133–143.10.1093/toxsci/kfr149Suche in Google Scholar

[26] Bahuguna A, Khan I, Bajpai VK, Kang SC. Bangladesh J. Pharmacol. 2017, 12, 115–118.10.3329/bjp.v12i2.30892Suche in Google Scholar

[27] Mosmann T. J. Immunol. Methods 1983, 65, 55–63.10.1016/0022-1759(83)90303-4Suche in Google Scholar

[28] Rozamus LW, Sharma P. Singapura Patent No. 11201702980Q A1. 2017.Suche in Google Scholar

[29] Alshetaili AS, Anwer MK, Alshahrani SM, Alalaiwe A, Alsulays BB, Ansari MJ, Imam F, Alsheri S. Trop. J. Pharm. Res. 2018, 17, 1263–1269.10.4314/tjpr.v17i7.6Suche in Google Scholar

[30] Anwer MK, Jamil S, Ansari MJ, Iqbal M, Imam F, Shakeel F. Mat. Res. Innov. 2016, 20, 193–197.10.1179/1433075X15Y.0000000049Suche in Google Scholar

[31] Bohrey S, Chaurasiya V, Pandey A. Nano. Converg. 2016, 3, 2–7.10.1186/s40580-016-0065-ySuche in Google Scholar PubMed PubMed Central

Received: 2019-08-09
Accepted: 2019-09-04
Published Online: 2019-10-22
Published in Print: 2019-11-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Heruntergeladen am 11.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/polyeng-2019-0265/html?lang=de
Button zum nach oben scrollen